))
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest ...
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Erika Hamilton, MD The ELECTRA trial is seeking to evaluate the combination of elacestrant with abemaciclib in patients with ER+/HER2- metastatic breast cancer regardless of metastatic site and ESR1 status to see if this could be an all-oral treatment option before using fulvestrant-based combinations…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Douglas Tremblay, MD Based on three randomized-controlled trials, the JAK inhibitor momelotinib has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly in patients with myelofibrosis. But what do we know about its long-term safety? That’s what a recent study explor…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Mary Frances McMullin, MD The MOMENTUM study evaluated the impact of the treatment option momelotinib on patient-reported outcomes, including symptom burden and overall quality of life. Joining Dr. Charles Turck to share the key findings and potential implications for myelofibrosis care is Dr. Mary Fr…
…
continue reading
Host: Gates B. Colbert, MD Guest: Ryan Cassaday, MD According to the available long-term data, CAR T-cell therapy boosts overall survival and durable remission rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Given this data, it’s important to know how we can best identify appropriate patients for this approac…
…
continue reading
Host: Matt Birnholz, MD The SIMPLIFY-2 trial compared the efficacy of momelotinib to best available therapy, which was primarily continued ruxolitinib, in patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor. According to the findings, momelotinib potentially offers better outcomes and a more comprehensive managem…
…
continue reading
Guest: Betsy O'Donnell, MD Plasma cell disorders range from multiple myeloma to the monoclonal gammopathy of undetermined significance (MGUS), which is a benign condition that affects anywhere between 3 and 10 percent of the population starting at age 50. However, about 1 percent of people per year who have MGUS will progress to multiple myeloma. H…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Joshua E. Reuss, MD The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss…
…
continue reading
1
Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
Host: Saad Z. Usmani, MD, MBA, FACP Guest: Joshua Richter, MD Guest: Ashley Steinberger, APP Release date: 8/15/2024 Expiration date: 8/15/2025 Estimated time to complete: 1.0 hour This activity is not accredited for CME/CE credit. This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multipl…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Christopher Chambers, MD Guest: Adam H. Buchanan, MS, MPH Since multi-cancer early detection (MCED) testing is a new technology, there’s been some discussion in the field about the impact it may have on patients, especially in terms of potential psychological harm like anxiety related to positive test…
…
continue reading
Host: Jody Takemoto, PhD Guest: David Braun Identifying biomarkers for renal cell carcinoma (RCC) is critical since they can help direct our therapeutic approach, which is why several techniques that may be able to uncover new biomarkers are currently being investigated. Joining Dr. Jody Takemoto to review those techniques and their potential impac…
…
continue reading
Host: Jody Takemoto, PhD Guest: David Braun, MD, PhD A recent study investigated whether renal cell carcinoma (RCC) molecular subtypes have any impact on treatment outcomes. Here to share the surprising findings and their implications is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology a…
…
continue reading
Host: Jody Takemoto, PhD Guest: Robert Wong, MD Since the guidelines for diagnosing and treating hepatocellular carcinoma are often lengthy and complicated, it can be difficult for clinicians to stay up to date on the current recommendations and implement them in clinical practice. That’s why a team with the HCC Steering Committee of the Chronic Li…
…
continue reading
1
Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
Host: Jesus G. Berdeja, MD Guest: Nicholas G. Barkemeyer, MPAS Guest: Ajai Chari, MD Guest: Harvey Church Guest: Amy Gebhardt Guest: Steven Morrow Release date: 7/18/2024 Expiration date: 7/18/2025 Estimated time to complete: 1.0 hour This activity is not accredited for CME/CE credit. This episode of Myeloma Matters features discussions of bispecif…
…
continue reading
Host: Matt Birnholz, MD Guest: Saad Kenderian M.B, Ch.B CAR T-cell therapy has been revolutionary in the treatment of blood cancers like chronic lymphocytic leukemia and multiple myeloma, and according to recent research, this therapeutic approach may also help patients with thyroid cancer. However, there are several challenges associated with appl…
…
continue reading
Host: Brian P. McDonough, MD, FAAFP Guest: Betsy O'Donnell, MD Guest: Tomasz Beer, MD, FACP Should a patient get a positive multi-cancer early detection (MCED) test result, there are two diagnostic resolution pathways proposed for localizing and confirming that result. Joining Dr. Brian McDonough to break down those two pathways and how we can opti…
…
continue reading
Guest: Phillip H. Kuo, MD, PhD One of the major changes that's occurred very recently in the field of neurodegenerative disease and Alzheimer's disease, specifically, are the recently approved antibody therapies that remove amyloid from the brain, which is one of the culprit proteins in Alzheimer's disease. To learn more about this presentation fro…
…
continue reading
Host: Jody Takemoto, PhD Guest: Robert Wong, MD Hepatitis B is one of the leading causes of liver cancer globally, underscoring the importance of screening, diagnosing, and treating patients appropriately. However, there are several considerations to keep in mind when caring for patients with hepatocellular carcinoma with hepatitis B co-infection, …
…
continue reading
